Core Viewpoint - Ekso Bionics Holdings, Inc. has entered into a private placement agreement to raise approximately $5.9 million through the sale of Series B Preferred Stock and warrants, aimed at enhancing its working capital and corporate purposes [1][3]. Group 1: Private Placement Details - The company will sell 5,852 shares of Series B Preferred Stock with a stated value of $1,000 per share, convertible into 711,922 shares of common stock at a conversion price of $8.22 per share [2]. - The warrants will allow the purchase of up to 355,960 shares of common stock at an exercise price of $8.22 per share, expiring five years from the initial exercise date [2]. - The closing of the private placement is expected around January 22, 2026, pending customary closing conditions [3]. Group 2: Financial Implications - The gross proceeds from the private placement are anticipated to be approximately $5.9 million before deducting fees and expenses [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]. - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7].

Group 1 - The core focus of the news is the investigation by Monteverde & Associates PC into EKSO Bionics Holdings, Inc. regarding its merger with Applied Digital Cloud, which is expected to result in EKSO shareholders owning approximately 3% of the combined company [1] - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm operates from the Empire State Building in New York City and emphasizes its successful track record in class action securities litigation [2][4] Group 2 - The firm invites shareholders of EKSO Bionics who have concerns or seek additional information to contact them for free [3] - Monteverde & Associates PC highlights its national presence and experience in trial and appellate courts, including the U.S. Supreme Court [2] - The firm provides a platform for shareholders to inquire about their rights and potential recovery options related to the merger [3][4]

Core Viewpoint - H.C. Wainwright downgraded Ekso Bionics to Neutral from Buy due to its non-binding merger agreement with Applied Digital Cloud, indicating a shift from its core business strategy [1] Group 1: Company Actions - Ekso Bionics entered into a non-binding merger agreement with Applied Digital Cloud, which is seen as a prudent move given the tough financial environment [1] - The downgrade reflects concerns that Ekso Bionics is moving away from its primary focus on commercializing exoskeletons for health and industrial applications [1]

Core Viewpoint - Ekso Bionics (EKSO) shares surged nearly 100% following Applied Digital's (APLD) announcement of spinning off its cloud segment, which will merge with Ekso to form a new entity called ChronoScale [1]. Group 1: Company Developments - The merger with the spun-off cloud segment is part of a strategic review aimed at unlocking shareholder value for Ekso Bionics [3]. - Ekso Bionics operates in a rapidly expanding market for robotic exoskeletons, which are used for rehabilitation and workplace safety [4]. - Recent healthcare partnerships and industrial deployments have led to a significant revenue growth of 105% sequentially in Q3 [5]. Group 2: Market Position and Valuation - Despite the recent surge, EKSO stock is still down approximately 40% from its year-to-date high [2]. - The price-sales (P/S) multiple for Ekso Bionics is less than 1x, making it an attractive early-stage investment in its market [4]. - The consensus rating for EKSO shares is currently "Moderate Buy," with the highest price target of $9.50 indicating a potential downside of nearly 10% from current levels [7]. Group 3: Technical Analysis - EKSO shares are trading above major moving averages, with a long-term relative strength index (100-day) at nearly 56, suggesting that bullish momentum is still strong [5]. - Investors typically reward companies involved in spinoffs due to anticipated improvements in efficiency and growth prospects [3].

Market Overview - The U.S. stock market is closing 2025 on a cautious note, with major index futures edging lower, extending a three-session losing streak, and hopes for a year-end "Santa Claus" rally fading [1] - Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 poised for its third consecutive year of double-digit gains [1] Premarket Trading and Futures Movements - As of early Wednesday, U.S. stock futures indicated a softer open, with Nasdaq 100 futures down 0.43%, S&P 500 futures down 0.28%, and Dow Jones futures down 0.14% [2] - The S&P 500, Nasdaq Composite, and Dow Jones all finished slightly lower on Tuesday, marking the third consecutive day of losses [2] Commodities Market - Crude oil futures were trading lower by 0.38%, around $57.72 per barrel, while Gold Spot was down 0.35% to approximately $4,324.59 per ounce [3] Major Market Indexes Performance - The S&P 500 is on track for an annual gain of 17-18%, the Dow Jones has advanced 13-14%, and the Nasdaq Composite has jumped nearly 21% in 2025 [4] - This performance marks the S&P 500's third consecutive year of double-digit returns, a rare achievement since the 1940s [4] Federal Reserve Outlook - The Federal Reserve is expected to cut rates in 2026, with uncertainty regarding the extent and pace due to internal divisions and mixed economic data [6] - The FOMC approved a quarter-point reduction in December 2025, bringing the main interest rate to a range between 3.5% and 3.75% [6] - Inflation remains above the Fed's 2% target, with unemployment rising to 4.6% in November and only 64,000 jobs added [6] Corporate Developments - Vanda Pharmaceuticals shares surged over 18% after receiving FDA approval for its drug NEREUS [13] - Nike shares rose 1.54% following CEO Elliott Hill's purchase of approximately $1 million in company shares [13] - Nvidia's stock surged approximately 180% in 2025, driven by robust demand for AI chips, with ByteDance planning to increase spending on Nvidia's AI chips to around $14 billion in 2026 [13] - Urgent.ly Inc. shares rose significantly after the adjournment of its annual stockholder meeting [13] - Applied Digital announced a proposed merger with EKSO Bionics, leading to a 40% surge in EKSO shares [13] - FONAR Corporation shares surged 28.4% after confirming its acquisition by an insider-led group [13] - Society Pass Incorporated shares jumped 16.4% following a newly priced public offering [13] - Palantir and Tesla saw their shares decline amidst concerns about technology giants' capital expenditures [13] - Boeing shares advanced 0.6% after being awarded an $8.58 billion contract by the Defense Department [13] - Meta Platforms shares ended up 1.1% following its acquisition of an AI startup for over $2 billion [13]

Core Viewpoint - Applied Digital Corp (NASDAQ: APLD) plans to spin off its cloud business and merge with Ekso Bionics (EKSO) to form a new entity called "ChronoScale" [1] Group 1: Company Performance - APLD shares have experienced volatility, dropping from a 20-year high of $40.20 on October 16 to around $24.83, with recent trading near breakeven [2] - Since the beginning of the year, APLD's stock has increased by 225% [2] Group 2: Market Dynamics - The stock of Ekso Bionics (EKSO) has surged by 94.1%, reaching $10.60 [1] - Short interest in APLD is significant, representing 33.5% of the available float, indicating a high level of bearish sentiment [4] - It would take approximately three days for short sellers to cover their positions based on APLD's average trading volume [4]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between EKSO Bionics Holdings, Inc. and Applied Digital Cloud for EKSO shareholders [1][2]. Group 1: Investigation Details - The investigation focuses on whether EKSO and its board violated federal securities laws and/or breached fiduciary duties by not obtaining the best possible consideration for shareholders [2]. - The investigation also questions if EKSO disclosed all material information necessary for shareholders to adequately assess and value the merger [2]. Group 2: Potential Actions - On behalf of EKSO shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief related to the proposed transaction [3]. - The legal action would be handled on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [3]. Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4].

Core Viewpoint - Applied Digital and EKSO Bionics announced a proposed business combination to form ChronoScale Corporation, aimed at creating a focused GPU platform for next-generation AI workloads, addressing the growing demand for GPU-accelerated cloud infrastructure [1][2]. Group 1: Proposed Transaction Details - The proposed transaction involves merging Applied Digital's cloud computing business with EKSO, resulting in ChronoScale, which will focus on delivering high-performance compute solutions tailored for AI workloads [1][2]. - Upon completion, Applied Digital is expected to own approximately 97% of the combined entity, with both Applied Digital Cloud and EKSO continuing to operate independently [3]. Group 2: Strategic Rationale - The separation of the accelerated compute platform from Applied Digital's data center operations will allow both businesses to scale independently and pursue distinct growth strategies [2]. - ChronoScale is designed for customers needing predictable performance and rapid deployment, without the limitations of generic cloud environments [2]. Group 3: Financial Performance - Applied Digital Cloud generated approximately $75.2 million in revenue over the twelve months ending August 31, 2025, indicating strong demand for dedicated accelerated compute services [4]. Group 4: Future Outlook - The proposed transaction is expected to close in the first half of 2026, pending customary due diligence and regulatory approvals [6]. - ChronoScale aims to leverage Applied Digital's existing infrastructure to enhance deployment timelines and reduce execution risks as GPU demand increases [5].

Core Viewpoint - Ekso Bionics Holdings, Inc. announced it will become the exclusive U.S. sales agent and distributor for MediTouch's BalanceTutor rehabilitation system, leading to a significant drop in its stock price by 12.75 percent to $3.97 [1] Group 1: Stock Performance - Ekso Bionics shares fell from a previous close of $4.5502 to $3.97, marking a decline of $0.5802 [1] - The stock opened at $4.25 and has traded within a range of $3.5100 to $4.4635 on the same day, with a trading volume of 5.05 million shares [2] - The company's 52-week stock price range is between $2.73 and $14.97 [2] Group 2: Product Announcement - The BalanceTutor rehabilitation system utilizes a patented 4D perturbation treadmill designed to simulate real-world balance challenges, enhancing patient safety and rehabilitation outcomes [1]

Core Insights - Ekso Bionics has entered into an agreement with MediTouch to become the exclusive authorized sales agent and distributor of the BalanceTutor rehabilitation system in the United States [1][3] Group 1: Product Overview - The BalanceTutor is a unique rehabilitation system featuring a patented 4D perturbation treadmill that allows patients with balance impairments to respond to unexpected disturbances while walking [2] - The treadmill can move in multiple directions (forward, backward, side-to-side) to simulate realistic balance challenges, ensuring patient safety through an overhead support frame [2] Group 2: Strategic Implications - The partnership with MediTouch is expected to enhance Ekso Bionics' market reach and align with its existing enterprise health exoskeleton solutions, targeting both inpatient and outpatient rehabilitation facilities [3] - The collaboration is seen as a significant milestone for MediTouch, aiming to increase access to innovative rehabilitation technology and assist more individuals in regaining balance and independence [3] Group 3: Company Background - Ekso Bionics specializes in developing exoskeleton solutions that enhance human strength, endurance, and mobility across medical and industrial applications, focusing on improving health and quality of life [4] - MediTouch is committed to creating advanced rehabilitation solutions for various healthcare settings, empowering clinicians and patients with effective rehabilitation tools [5]